Drug Delivery Differentiators with Syncromune's Eamonn Hobbs

Business Of Biotech

We love to hear from our listeners. Send us a message.

Syncromune's Sync-T solid tumor therapeutic platform is, in a word, complex. The company's three phase 1 programs combine T-cell science with a proprietary drug delivery device to target solid tumors, specifically metastatic breast, non-small-cell lung, and castrate-resistant prostate cancers. But, while orchestrating a successful drug/device combination therapy presents unique regulatory challenges and requires a diverse array of in-house skillsets, President and CEO Eamon Hobbs is confident. He's done this before, and Syncromune's lead candidate has just been fast-tracked by the FDA. On this episode of the Business of Biotech, Hobbs shares his perspectives on bringing novel drug/device combination therapies to market, and reflects on a career dedicated to the drug delivery craft and demonstrated by his leadership at Antares Pharma, Delcath Systems, AngioDynamics.

Access this and hundreds of episodes of the Business of Biotech videocast under the Listen & Watch tab at bioprocessonline.com.

Subscribe to our monthly Business of Biotech newsletter.
Get in touch with guest and topic suggestions: [e-mail]
Find Matt Pillar on LinkedIn: https://www.linkedin.com/in/matthewpillar/

章

1. Advancing Bioprocessing Technology and Delivery (00:00:00)

2. Unforeseen Challenges in Medical Device Innovation (00:10:15)

3. Navigating FDA Approval Hurdles (00:25:32)

4. Revolutionizing Cancer Treatment With Synchromune (00:29:36)

5. Complexity and Innovation in Drug Devices (00:36:30)

6. Integrating Drug and Device Expertise (00:49:03)

7. Navigating Clinical Procedural Application Strategy (01:00:20)